Breaking News Instant updates and real-time market news.

CLBS

Caladrius

$2.64

-0.06 (-2.22%)

13:01
11/17/19
11/17
13:01
11/17/19
13:01

Caladrius reports 'positive' results for CLBS16 from ESCaPE-CMD trial

Caladrius Biosciences presented results from the ESCaPE-CMD trial of Caladrius's autologous CD34+ cell therapy, CLBS16, at the American Heart Association Scientific Sessions 2019. Data showed highly statistically significant improvement in coronary flow reserve correlating with symptom relief for patients with coronary microvascular dysfunction after a single intracoronary injection of CLBS16. The results for patients who have completed the six-month follow-up to date were presented, with the results from the remaining patients expected by the end of 2019. "CLB16 represents a potential breakthrough for the treatment of CMD, a condition that affects millions in the U.S. and that disproportionately afflicts women. This is the first time that a therapy has shown the ability to durably increase coronary flow reserve and potentially reverse CMD after a single dose. These reported results clearly support the premise that manageable cell-based tissue regeneration is possible in patients with CMD," said David Mazzo, CEO of Caladrius. "The reported results from the ESCaPE-CMD trial bring us one step closer to realizing the promise of CD34+ cell therapy to augment microvasculature in the heart enabling the restoration of health rather than simply management of disease."

CLBS Caladrius
$2.64

-0.06 (-2.22%)

11/20/18
HCWC
11/20/18
INITIATION
Target $18.5
HCWC
Buy
Caladrius assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis assumed coverage of Caladrius Biosciences with a Buy rating and $18.50 price target. Based on a "strong management team and strong pipeline focus, Caladrius' thesis has been stabilized and is positioned for success," Pantginis tells investors in a research note. He points out the company is developing two technology platforms, with the lead based on CD34+ cells' playing a role in ischemic repair.
01/24/19
HCWC
01/24/19
NO CHANGE
Target $18.5
HCWC
Buy
Caladrius an 'intriguing opportunity' near cash levels, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis calls shares of Caladrius Biosciences an "intriguing opportunity" trading at near cash levels. A disconnect exists in evaluating the investment case for Caladrius' assets, which are supported by "compelling" clinical data, Pantginis tells investors in a research note. The analyst looks beyond the company's CD34+ cell therapy platform and highlights its second platform, T Regulatory Cell Therapy. He says the upcoming Phase 2 clinical readout using CLBS03 in Type 1 diabetes patients is the first major 2019 catalyst for Caladrius. Pantginis reiterates a Buy rating on the shares with an $18.50 price target.

TODAY'S FREE FLY STORIES

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

07:19
12/09/19
12/09
07:19
12/09/19
07:19
Conference/Events
Autolus Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

SPCE

Virgin Galactic

$7.28

0.07 (0.97%)

07:17
12/09/19
12/09
07:17
12/09/19
07:17
Initiation
Virgin Galactic initiated  »

Morgan Stanley cites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

TCBI

Texas Capital

$57.82

0.76 (1.33%)

, IBTX

Independent Bank

$59.23

1 (1.72%)

07:15
12/09/19
12/09
07:15
12/09/19
07:15
Hot Stocks
Independent Bank, Texas Capital Bancshares enter $5.5B all-stock merger »

Texas Capital Bancshares…

TCBI

Texas Capital

$57.82

0.76 (1.33%)

IBTX

Independent Bank

$59.23

1 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

$41.25

0.11 (0.27%)

07:15
12/09/19
12/09
07:15
12/09/19
07:15
Recommendations
Zai Lab analyst commentary  »

Citi opens 'positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGI

Pattern Energy

$27.45

0.02 (0.07%)

07:14
12/09/19
12/09
07:14
12/09/19
07:14
Hot Stocks
Pattern Energy announces expiration of 'Go-Shop Period' »

Pattern Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$171.49

7.13 (4.34%)

07:12
12/09/19
12/09
07:12
12/09/19
07:12
Downgrade
3M rating change  »

Citi downgrades 3M to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

FTV

Fortive

$72.86

0.5 (0.69%)

, MMM

3M

$171.49

7.13 (4.34%)

07:11
12/09/19
12/09
07:11
12/09/19
07:11
Upgrade
Fortive, 3M rating change  »

Citi upgrades Fortive to…

FTV

Fortive

$72.86

0.5 (0.69%)

MMM

3M

$171.49

7.13 (4.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

ORAN

Orange SA

$15.02

-0.055 (-0.36%)

07:10
12/09/19
12/09
07:10
12/09/19
07:10
Downgrade
Orange SA rating change  »

Orange SA downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMDA

Kamada

$7.36

-0.025 (-0.34%)

07:10
12/09/19
12/09
07:10
12/09/19
07:10
Hot Stocks
Kamada enters into binding term sheet, sees product adding $8M-$10M in revenue »

Kamada announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

07:09
12/09/19
12/09
07:09
12/09/19
07:09
Hot Stocks
Canadian Solar authorizes $150M share repurchase program »

Canadian Solar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETNB

89bio

$28.38

0.86 (3.13%)

07:09
12/09/19
12/09
07:09
12/09/19
07:09
Initiation
89bio initiated  »

89bio initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONG

Akazoo

$5.40

-0.12 (-2.17%)

07:08
12/09/19
12/09
07:08
12/09/19
07:08
Earnings
Akazoo reports Q3 EPS EUR0.03 vs, EUR0.02 last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECC

Eagle Point Credit

$15.03

-0.01 (-0.07%)

07:08
12/09/19
12/09
07:08
12/09/19
07:08
Upgrade
Eagle Point Credit rating change  »

Eagle Point Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$122.36

1.6 (1.32%)

07:07
12/09/19
12/09
07:07
12/09/19
07:07
Conference/Events
Texas Instruments management to meet with UBS »

Dinner Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 16

    Dec

KALV

KalVista

$14.36

0.25 (1.77%)

, MRK

Merck

$88.84

0.09 (0.10%)

07:06
12/09/19
12/09
07:06
12/09/19
07:06
Hot Stocks
KalVista says KVD001 does not meet primary endpoint »

KalVista Pharmaceuticals…

KALV

KalVista

$14.36

0.25 (1.77%)

MRK

Merck

$88.84

0.09 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

VTNR

Vertex Energy

$1.59

(0.00%)

07:05
12/09/19
12/09
07:05
12/09/19
07:05
Initiation
Vertex Energy initiated  »

Vertex Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.20

-0.01 (-0.03%)

07:05
12/09/19
12/09
07:05
12/09/19
07:05
Conference/Events
AT&T management to meet with UBS »

Dinner Meeting with CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

NOW

ServiceNow

$272.19

-0.94 (-0.34%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Conference/Events
ServiceNow management to meet with UBS »

Dinner Meeting with Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Hot Stocks
Rocket Pharmaceuticals announces preliminary data from RP-L201 Phase 1/2 trial »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Recommendations
Agios Pharmaceuticals analyst commentary  »

Cantor sees Agios trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:01
12/09/19
12/09
07:01
12/09/19
07:01
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

CI

Cigna

$198.96

3.44 (1.76%)

07:00
12/09/19
12/09
07:00
12/09/19
07:00
Conference/Events
Cigna management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 06

    Feb

AMAT

Applied Materials

$56.60

0.77 (1.38%)

06:59
12/09/19
12/09
06:59
12/09/19
06:59
Conference/Events
Applied Materials management to meet with UBS »

Breakfast Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CGC

Canopy Growth

$18.65

0.07 (0.38%)

, STZ

Constellation Brands

$183.60

1.13 (0.62%)

06:58
12/09/19
12/09
06:58
12/09/19
06:58
Recommendations
Cantor sees over 66% chance of Constellation bidding for Canopy Growth »

Cantor Fitzgerald analyst…

CGC

Canopy Growth

$18.65

0.07 (0.38%)

STZ

Constellation Brands

$183.60

1.13 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

MTG

MGIC Investment

$14.10

-0.03 (-0.21%)

06:58
12/09/19
12/09
06:58
12/09/19
06:58
Hot Stocks
MGIC Investment issues November operating statistics »

MGIC Investment issued an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.